HIT Perspectives Biopharma Insights provides pharma news, perspectives and updates on health care information technologies that affect the Biopharma industry. Articles provide insights to help pharmaceutical companies thrive in an EHR world and stay ahead of cross-cutting issues affecting patients, providers, payers, and vendors.
Download the April 2018 issue of HIT Perspectives Biopharma Insights by clicking the thumbnail to the right. – PDF – 
2018
HIT Perspectives Biopharma Insights (April 2018) –
Apple’s New App for Personal Health Information: Is It a Game Changer? | 10 Takeaways from HIMSS| The Da Vinci Project: Helping Payers and Providers Get the Most From Value-Based Care
HIT Perspectives Biopharma Insights (February 2018) –
Drug Benefit Cost Information at the Point of ePrescribing: What Lies Ahead| Top Trends to Watch in 2018| Virtual Visits: Now Coming to Homes, Doctors and Pharmacies
2017
HIT Perspectives Biopharma Insights (November 2017)–
Following What the Doctor Ordered: Addressing Medication Noncompliance | The Impact of New, Nonproprietary Naming Convention for Biologics and Biosimilars: 7 Key Findings| ONC to Significantly Scale Back EHR Certification and Enrollment
HIT Perspectives Biopharma Insights (September 2017)–
The Electronic Health Record: A Valuable Tool for Brand Teams | Interoperability and Standards Will Be Areas of Focus Through Year End| Automating Enrollment for Specialty Prescriptions
HIT Perspectives Biopharma Insights (June 2017)–
Why Population Health Management Should Matter to Pharmaceutical Manufacturers | HHS Moves Ahead in Personnel and Health IT| New Maturity Model Will Help Spur Adoption of Electronic Prior Authorization
HIT Perspectives Biopharma Insights (April 2017)–
Eight Takeaways from HIMSS 2017 | FHIR Sets the Stage for Targeted Applications for Payers and Providers| Stakeholder Impacts of the AMA’s Prior Authorization Reform Proposal
HIT Perspectives Biopharma Insights (February 2017) –
10 Trends to Watch in 2017| Will MACRA Be in the Crosshairs for Repeal and Replacement?| What the 21st Century Cures Act Means for Health IT
2016
HIT Perspectives Biopharma Insights (November 2016) –
Working Smarter, Not Harder: Helping Clinicians Optimize Use of EHRs | Computerized Order Sets Help Physicians Save Time and Improve Care| Electronic Dosing Instructions: Opportunities for Sales Teams
HIT Perspectives Biopharma Insights (September 2016) –
EHRs: A New Dissemination Tool for Patient Education Materials | Surescripts Issues its 2015 National Progress Report|Electronic Prior Authorization: Just What the Doctor Ordered (Almost)
HIT Perspectives Biopharma Insights (June 2016) –
New Proposed Regulation Rebrands and Retools Meaningful Use | Cutting Through the Confusion Surrounding Electronic Formulary and Benefit Checks | Retail Medical Clinics: Untapped Resources for Patient Education
HIT Perspectives Biopharma Insights (April 2016)–
Ten Takeaways from HIMSS16 | Integrating EHRs and PDMPs: How Vendors Can Get Ahead of the Curve | Alerting Prescribers for Biosimilar Substitution to Protect Patient Safety
HIT Perspectives Biopharma Insights (February 2016) –
Top Ten Health IT Trends for 2016 | Getting Doctors Ready for New York’s War on Opioid Abuse | Meaningful Use: Not Entirely Gone but Certainly Not Forgotten
2015
HIT Perspectives Biopharma Insights (November 2015) –
EHRS Can Expand the Quality and Scope of Physician Practices | Physicians’ Health, IT Priorities to Focus on ICD-10 and Meaningful Use | Why Care About the EHR Interoperability Brouhaha?
HIT Perspectives Biopharma Insights (September 2015) –
Five Ways Pharmaceutical Companies Can Leverage EHR Market Changes and Challenges | Better Formulary and Benefit Information Pay Off for Payers | FDA to Assess Role for EHRs in Clinical Trials
HIT Perspectives Biopharma Insights (June 2015)–
Surescripts Issues 2014 National Progress Report | Real-Time Benefit Check: Coming to the Point of Care | Efforts Under Way to Make REMS More Efficient and Less Burdensome
HIT Perspectives Biopharma Insights (May 2015) –
HIMSS15: On FHIR and 6 Other Key Takeaways | Meaningful Use Stage 3 Creates Opportunities for Pharma | The Impact of MU Stage 3 on Patient Engagement
HIT Perspectives Biopharma Insights (February 2015)–
Exciting Changes Ahead in 2015 for HealthIT | New York Leads Way in Electronic War Against Opiod Abuse | EHRs: A Tool to Improve Vaccine Use
2014
HIT Perspectives Biopharma Insights (December 2014) –
Biosimilars: Opportunity Knocks – Building a Better Technology Mousetrap | Improved Prescription Information: The Key to Closing the Medication Adherence Gap | Drug Databases: A Growing Resource for Patient Care and Safety
HIT Perspectives Biopharma Insights (September 2014)–
What’s Next for EHR Market Consolidation? | Growing Use of Oral Specialty Medications to Spur ePrescribing Adoption | Real-World Evidence Comes to Mainstream Health Care
HIT Perspectives Biopharma Insights (July 2014) –
Meaningful Use Learnings for Pharmaceutical Companies | Deciphering the Mystery of Population Health Management |Surescripts Stats Show ePrescribing Rounds Third Base
HIT Perspectives Biopharma Insights (April 2014)–
Guidelines and Best Practices: Ripe for an Assist from Managed Markets Teams | What’s Next for Meaningful Use? | Improving Adoption of Clinical Decision Support
HIT Perspectives Biopharma Insights (March 2014)–
Improving ePrescribing as an Important Tool for Managed Markets | The Top Ten Health IT Trends for 2014 | Accelerating ePrescribing for Controlled Substances
